Editor's Highlights—June 2026
International Journal of Dermatology · 2026-06 · 65 (6) · 1131-1132
DOI: 10.1111/ijd.70463 ↗At a glance
Editorial in International Journal of Dermatology, published online on 2026-05-02. Written by Lajos Kemény. Institution: Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary. Major MEDLINE topics: Dermatitis, Atopic, Psoriasis, Hidradenitis Suppurativa. 5 references.
Abstract (original language)
Major advances have broadened the therapeutic landscape of inflammatory skin diseases. In psoriasis, alongside the tyrosine kinase 2 (TYK2) inhibitor deucravacitinib, the United States Food and Drug Administration (FDA) has approved the first oral interleukin‐23 (IL‐23) receptor antagonist peptide, icotrokinra. In atopic dermatitis, new data have emerged on stapokibart, an interleukin‐4 receptor alpha subunit (IL‐4Rα) inhibitor introduced in China. In hidradenitis suppurativa, glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) are also gaining increasing attention as adjunctive therapy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
ORCID profiles: Lajos Kemény
Cite
APA
Kemény, L. (2026). Editor's Highlights—June 2026. International Journal of Dermatology, 65(6), 1131-1132. https://doi.org/10.1111/ijd.70463
Vancouver
Kemény L. Editor's Highlights—June 2026. International Journal of Dermatology. 2026;65(6):1131-1132. doi:10.1111/ijd.70463
BibTeX
@article{Kemny2026,
author = {Kemény, Lajos},
title = {Editor's Highlights—June 2026},
journal = {International Journal of Dermatology},
year = {2026},
volume = {65},
number = {6},
pages = {1131--1132},
doi = {10.1111/ijd.70463}
}
EUVIMED